Pharmafield - Addressing the long-term effects of COVID-19

Addressing the long-term impacts on sickness and disease as a consequence of the COVID-19 pandemic, both causal and additive, will be a continuing challenge for the healthcare sector as it moves through the recovery and restoration agenda.

Full article here:

https://pharmafield.co.uk/featured/addressing-the-long-term-effects-of-covid-19/
By Johnny Skillicorn-Aston and Jeremy Hooper -August 3, 2020

Specialised Medicines - We need to identify unmet need and create the solutions - To start building a new model of care for pharmacy, the needs of working-age adults could be used as the basis for inter-contractor dialogue, say James Roach and Johnny Skillicorn-Aston of Conclusio

The homecare model for cancer must recognise the vital role of community pharmacists, argue James Roach and Johnny Skillicorn-Aston - Specialised Medicine May 2020

In the short to medium term, a cancer diagnosis focuses the mind on the disease and all that accompanies it: the prognosis, treatments, and effects on one’s life. However, for many people receiving a cancer diagnosis, especially those who are older, it will add to one or more pre-existing morbidities. Although treatment in the first instance may need to be acute, it will be the effective long-term management of an additional chronic condition that makes the difference to patients.

Full article here - https://www.specialisedmedicine.co.uk/articles/community-pharmacy-is-key-to-new-models-of-cancer-care/

Conclusio’s Johnny Skillicorn-Aston and James Roach consider the true meaning of patient-centricity in clinical trials : Pharma Times

Full article herehttp://www.pharmatimes.com/thought_leadership/creating_common_endeavours_1332717

What’s the point of difference?

Pharma and the NHS - barriers to partnership working are breaking, it’s time for pharma to build on its differences to be more than a supplier.

James Roach and Johnny Skillicorn-Aston - Pharmafield Magazine

https://pharmafield.co.uk/pf-magazine/

Johnny Skillicorn-Aston and James Roach argue that partnership working between the NHS and the pharmaceutical industry must now engage patients
In specialised medicines, we have witnessed a step change in the care of patients living with highly active relapsing multiple sclerosis (MS). Across specialised commissioning, there now appears to be a real appetite for medicines innovation and optimisation that will contribute to the transformation and savings that the NHS wants to achieve as part of the LTP. As NHS England Chief Executive Officer (CEO) Simons Stevens said: ‘Preparations are underway to make sure the NHS can adopt the next generation of treatments.
https://www.specialisedmedicine.co.uk/articles/a-step-change-in-specialised-medicines/

The important role community pharmacists can play as a source of initial advice and ongoing help in the management of heartburn and indigestion is one that is recognised by NICE and appreciated by customers - Opportunity knocks for OTC Omeprazole. The OTC launch of Pyrocalm Control Omeprazole 20mg Gastro-Resistant Tablets offers an opportunity for pharmacists to both promote self-care and reduce prescribing
https://www.pharmacymagazine.co.uk/gut-feeling

James Roach, in his NHS role, looks at the future for biosimilar medicines, surveys a future landscape where medicines management will be performed at ICS level, and suggests that pharma can be a crucial player in NHS transformation
https://wilmingtonhealthcare.com/what-next-for-biosimilars/

James Roach and Johnny Skillicorn-Aston, Conclusio
January 2020

Driving innovation in a modern NHS - What is pharma’s role and what does it mean for patients? Pharmafield

https://pharmafield.co.uk/in_depth/driving-innovation-in-a-modern-nhs/
James Roach and Johnny Skillicorn-Aston, Conclusio
December 2019

Let’s seize the opportunity to change the dynamic. Pharmacy needs to push the case for a change in the point of patient interaction and so help manage access pressures. Pharmacy Magazine -

https://www.pharmacymagazine.co.uk/lets-seize-the-opportunity-to-change-the-dynamic
Johnny Skillicorn-Aston, Director of Engagement and communication, Conclusio
October 2019

A recent roundtable event attended by academics, nutrition experts and health and industry leaders brought into sharp focus the issue of malnutrition and its consequences for health and wellbeing.

https://flickread.com/edition/html/index.php?pdf=5ddbee05a2dd8#15
From elsewhere - Amanda Barrell writing in PharmaPhorum

A move towards integrated care systems (ICS), complete with new primary care roles, and a greater focus on public health is shaking the healthcare system to its core. But what does this mean for industry?

Mike Proctor, recently retired chief executive of York Teaching Hospital NHS Foundation Trust, quoted in the articles "Iindustry could become a crucial part of this new world – but routes to success vary across the country."
He advised delegates to adopt a flexible, regional approach, be prepared to move from national to local priorities, and to build relationships with the new decision makers.
“There is a dream of a truly integrated social care, primary care, secondary care and mental health care. We do believe this is the right thing to do but the bottom line is there is no one size to fit all,” he said, adding that the only unifying factor was reducing hospital admissions. Don’t sell boxes, sell solutions. Develop products that keep people out of hospital – that is key. If you can find ways to keep people out of hospital and you can support that in some way, the door is open,”

The AAC should engage with patients to steer future innovation. James Roach and Johnny Skillicorn-Aston present an interesting case for localising the work of the Accelerated Access Collaborative - October 2019 https://www.specialised-commissioning.co.uk/articles/the-aac-should-engage-with-patients-to-steer-future-innovation/
Pharma and biosimilars in the medicines supply chain - September 2019://pharmafield.co.uk/in_depth/pharma-biosimilars-in-the-medicines-supply-chain/
Creating joint responsibility for healthcare - July 2019. https://pharmafield.co.uk/healthcare/creating-shared-responsibility-for-healthcare/
Framework for efficiencies through the Long Term Plan - June/July 2019, National Health Executive. http://www.nationalhealthexecutive.com/Health-Service-Focus/framework-long-term-plan
Pharma and the NHS working in Partnership - March 2019. https://pharmafield.co.uk/in_depth/pharma-and-nhs-working-in-partnership/
UK Pharma and Integrated Health Webinar - March 2018. https://www.brighttalk.com/webcast/9977/302033/uk-pharma-and-integrated-health
A Year in Pharma - December 2018 -
https://pharmafield.co.uk/in_depth/a-year-in-pharma-what-happened-in-pharma-in-2018/
Supporting GPs through Community Pharmacies - September/October 2018. http://www.nationalhealthexecutive.com/The-Scalpels-Daily-Blog/supporting-gps-through-community-pharmacies-
New Models of Care - July 2018. https://www.npa.co.uk/newmodelsofcare
Improving primary care with community pharmacy - December 2017. https://pharmafield.co.uk/healthcare/community-pharmacy-and-primary-care/
NPA unveils national innovation programme - October 2017. https://www.pharmacymagazine.co.uk/npa-unveils
InPharmacy - Winter 2017. James Roach: "It is absolutely clear that community pharmacy is the solution that we need to invest in – it’s my view that the NHS needs community pharmacy more than ever before."
https://www.npa.co.uk/wp-content/uploads/2017/12/Weathering-the-storm-dec-2017-feature-cover-article...

Developing a new type of think tank - October 2017. http://www.nationalhealthexecutive.com/Comment/developing-a-new-type-of-think-tank/185233
Making community pharmacy integral to STP solutions - July/August 2017. http://www.nationalhealthexecutive.com/Comment/making-community-pharmacy-integral-to-stp-solutions
The future of pharmacies - leading new models of care - June 2017. http://www.healthfoundry.org/news/2017/6/22/the-future-of-pharmacies-leading-new-models-of-community-based-care